| Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma RJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ... New England Journal of Medicine 380 (12), 1103-1115, 2019 | 2234 | 2019 |
| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 1548 | 2019 |
| Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma GK Abou-Alfa, G Lau, M Kudo, SL Chan, RK Kelley, J Furuse, ... NEJM evidence 1 (8), EVIDoa2100070, 2022 | 539 | 2022 |
| Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN … JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet Oncology 22 (1), 51-65, 2021 | 440 | 2021 |
| Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma … GK Abou-Alfa, SL Chan, M Kudo, G Lau, RK Kelley, J Furuse, ... Journal of Clinical Oncology 40 (4_suppl), 379-379, 2022 | 310 | 2022 |
| Скрининг рака молочной железы ВФ Семиглазов, ВВ Семиглазов, Д Дашян Практическая онкология 11 (2), 60-65, 2010 | 218 | 2010 |
| PL02. 01 durvalumab±tremelimumab+ chemotherapy as first-line treatment for mNSCLC: results from the phase 3 POSEIDON study M Johnson, BC Cho, A Luft, J Alatorre-Alexander, SL Geater, K Laktionov, ... Journal of Thoracic Oncology 16 (10), S844, 2021 | 71 | 2021 |
| Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial JM Llovet, M Kudo, P Merle, T Meyer, S Qin, M Ikeda, R Xu, J Edeline, ... The Lancet Oncology 24 (12), 1399-1410, 2023 | 45 | 2023 |
| Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a … A Psyrri, J Fayette, K Harrington, M Gillison, MJ Ahn, S Takahashi, ... Annals of Oncology 34 (3), 262-274, 2023 | 45 | 2023 |
| Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early … PA Fasching, A Bardia, V Quiroga, YH Park, I Blancas, JL Alonso, ... Journal of Clinical Oncology 40 (16_suppl), 589-589, 2022 | 24 | 2022 |
| Опухолевые маркеры при раке молочной железы ВФ Семиглазов, ВВ Семиглазов, Г Дашян, А Бессонов, Р Палтуев, ... Врач, 2-7, 2011 | 22 | 2011 |
| Индивидуализация адъювантной терапии рака молочной железы ВФ Семиглазов, ВВ Семиглазов, РМ Палтуев, ГА Дашян, АГ Манихас, ... Фарматека, 8-13, 2011 | 20 | 2011 |
| Адъювантная терапия рака молочной железы, направленная против рецептора HER2 ВФ Семиглазов, ВВ Семиглазов, ВГ Иванов, АА Бессонов, ДЕ Щедрин, ... Фарматека, 12-17, 2010 | 16 | 2010 |
| Неоадьювантная таргетная терапия рака молочной железы ВФ Семиглазов, ТЮ Семиглазова, АА Божок, АГ Манихас Эффективная фармакотерапия 6, 12-16, 2013 | 11 | 2013 |
| Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label … SA Hurvitz, A Bardia, V Quiroga, YH Park, I Blancas, JL Alonso-Romero, ... The Lancet Oncology 24 (9), 1029-1041, 2023 | 10 | 2023 |
| The experience of using percutaneous nephrolithotripsy and contact ureterolithotripsy in the complex treatment of urolithiasis. Preventive and clinical medicine. 2012;(4): 30–33 NS Tagirov, TH Nazarov, AG Vasilev Russ, 0 | 9 | |
| Antithrombotic therapy in oncology: contemporary concepts and pending problems AP Trashkov, AG Vasiliev, NV Tsygan, NV Khaitsev, SP Marchenko, ... Pediatrician (St. Petersburg) 3 (2), 3-19, 2012 | 8 | 2012 |
| HER2-позитивный рак молочной железы: стандартное и двойное таргетное лечение ВФ Семиглазов, АА Божок, ТЮ Семиглазова, АГ Васильев, ... Вопросы онкологии 59 (3), 341-346, 2013 | 7 | 2013 |
| Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer) GK Abou-Alfa, G Lau, M Kudo, SL Chan, RK Kelley, J Furuse, ... Future Oncology 19 (38), 2505-2516, 2023 | 6 | 2023 |
| Sovremennoe predstavlenie o nealkogol’noj zhirovoj bolezni pecheni [Modern understanding of non-alcoholic fatty liver disease] TV Brus, AG Vasil’ev Russian Biomedical Research 5 (1), 18-25, 2020 | 6 | 2020 |
